GI medical oncologists discuss MRD testing practices in colorectal cancer and provide insights on challenges associated with testing.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Pancreatic/Colorectal Adenocarcinoma Rates Have Increased in Young Adults
Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC
The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases
Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.
Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer
Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.